[go: up one dir, main page]

CA1326632C - Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer - Google Patents

Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Info

Publication number
CA1326632C
CA1326632C CA 581365 CA581365A CA1326632C CA 1326632 C CA1326632 C CA 1326632C CA 581365 CA581365 CA 581365 CA 581365 A CA581365 A CA 581365A CA 1326632 C CA1326632 C CA 1326632C
Authority
CA
Canada
Prior art keywords
particles
galanthamine
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 581365
Other languages
English (en)
Inventor
Bonnie Davis
Morris Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 581365 priority Critical patent/CA1326632C/fr
Application granted granted Critical
Publication of CA1326632C publication Critical patent/CA1326632C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 581365 1988-10-26 1988-10-26 Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer Expired - Lifetime CA1326632C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 581365 CA1326632C (fr) 1988-10-26 1988-10-26 Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 581365 CA1326632C (fr) 1988-10-26 1988-10-26 Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CA1326632C true CA1326632C (fr) 1994-02-01

Family

ID=27167974

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 581365 Expired - Lifetime CA1326632C (fr) 1988-10-26 1988-10-26 Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA1326632C (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038686A1 (fr) * 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Composition de galantamine a liberation controlee
EP1133230A1 (fr) * 1998-11-23 2001-09-19 Bonnie M. Davis Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
WO2007121537A1 (fr) 2006-04-26 2007-11-01 Alphapharm Pty Ltd Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2011064797A2 (fr) 2009-11-26 2011-06-03 Usv Limited Compositions pharmaceutiques à libération contrôlée de galantamine

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004242546B2 (en) * 1998-11-23 2008-05-15 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP1133230A1 (fr) * 1998-11-23 2001-09-19 Bonnie M. Davis Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
EP1133230A4 (fr) * 1998-11-23 2004-05-26 Bonnie M Davis Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
EP2311441A1 (fr) * 1998-11-23 2011-04-20 Bonnie M. Davis Formulation de dosage d'inhibiteurs de l'acétylcholinestestérase
AP1414A (en) * 1998-12-24 2005-06-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
BG65306B1 (bg) * 1998-12-24 2008-01-31 Janssen Pharmaceutica N.V. Лекарствена форма с контролирано освобождаване, съдържаща галантамин
CN100370990C (zh) * 1998-12-24 2008-02-27 詹森药业有限公司 控释加兰他敏组合物
US7160559B1 (en) 1998-12-24 2007-01-09 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CZ301658B6 (cs) * 1998-12-24 2010-05-19 Janssen Pharmaceutica N. V. Prostredky s rízeným uvolnováním galantaminu
HRP20010463B1 (en) * 1998-12-24 2011-02-28 Janssen Pharmaceutica N.V. Controlled release galantamine composition
WO2000038686A1 (fr) * 1998-12-24 2000-07-06 Janssen Pharmaceutica N.V. Composition de galantamine a liberation controlee
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
WO2007121537A1 (fr) 2006-04-26 2007-11-01 Alphapharm Pty Ltd Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
EP2010158B1 (fr) 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
WO2011064797A2 (fr) 2009-11-26 2011-06-03 Usv Limited Compositions pharmaceutiques à libération contrôlée de galantamine

Similar Documents

Publication Publication Date Title
KR0140492B1 (ko) 방출억제성 오피오이드 제형
CA1318600C (fr) Etodolac a liberation prolongee
DE3879080T2 (de) Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.
US4851226A (en) Chewable medicament tablet containing means for taste masking
US5169642A (en) Sustained-release drug dosage units
US5122384A (en) Oral once-per-day organic nitrate formulation which does not induce tolerance
DE69732113T2 (de) Schnelllösliche tablette enthaltend galanthaminhydrobromid
HU199677B (en) Process for producing retard pharmaceutical composition
PL172571B1 (pl) Doustny preparat morfiny PL PL PL
NZ238131A (en) Chewable medicament tablets formed from compressed coated granules; coating is a polymer blend masking taste and providing sustained release
CA1336069C (fr) Comprime de medicament contenant un produit masquant le gout
US5268182A (en) Sustained-release drug dosage units of terazosin
CZ282679B6 (cs) Použití 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazolu pro výrobu farmaceutického prostředku
DE3719818C2 (de) Pharmazeutische Zusammensetzung
CA1326632C (fr) Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer
US4968506A (en) Pharmaceutical dosage with core of N-acetyl cystein
US5853756A (en) Controlled release formulations of Ranitidine
EP0546846A1 (fr) Compositions pharmaceutiques à libération programmée
NZ552998A (en) Anti-histaminic composition
CA1099641A (fr) Traduction non-disponible
KR20030081027A (ko) 피복 고형 최면 제제
AU668376B2 (en) Antimalarial synergistic compositions containing benflumetol
CN108309949B (zh) 一种吗啡渗透泵片的制备方法及其产品
DE3736866A1 (de) Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
WO2014132226A1 (fr) Formulation dispersible stable de maléate d'artérolane et de pipéraquine et procédé de préparation de celle-ci

Legal Events

Date Code Title Description
MKEX Expiry

Effective date: 20110201